PE20080888A1 - HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1) - Google Patents
HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1)Info
- Publication number
- PE20080888A1 PE20080888A1 PE2007001396A PE2007001396A PE20080888A1 PE 20080888 A1 PE20080888 A1 PE 20080888A1 PE 2007001396 A PE2007001396 A PE 2007001396A PE 2007001396 A PE2007001396 A PE 2007001396A PE 20080888 A1 PE20080888 A1 PE 20080888A1
- Authority
- PE
- Peru
- Prior art keywords
- acil
- halogen
- diacil
- dgat1
- coa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA A-L1-B-C-D, EN DONDE A ES UN ALQUILO(C1-C20), ALCOXILO(C1-C20), CICLOALQUILO(C3-C12), ENTRE OTROS; L1 ES -(CH2)n-(CR4R4')p-(CH2)m-N(R3)-, -(CH2)n-(CR4R4')p-(CH2)m-N(R3)-C(S)-, -C(NH)-N(R3)-(CH2)n-(CR4R4')p-(CH2)m-, ENTRE OTROS, DONDE R3 ES H O ALQUILO INFERIOR(C1-C7); m, n Y p SON CADA UNO DE 0 A 2; R4 Y R4' SON CADA UNO H, HALOGENO, HIDROXILO, ALCOXILO INFERIOR(C1-C7), ENTRE OTROS; B ES UN COMPUESTO DE FORMULA (i), (ii), ENTRE OTROS, DONDE X1 Y X2' SON CADA UNO O, NH, S, ENTRE OTROS; X1', X2, X3 Y X4 SON CADA UNO N O CH; C ES UN COMPUESTO DE FORMULA (iii), ARILO(C6-C14), ENTRE OTROS, DONDE R1 ES H, CN, HALOGENO, CF3, ENTRE OTROS; R'1, R2 Y R'2 SON CADA UNO H, HALOGENO, CF3, ALQUILO INFERIOR(C1-C7), ENTRE OTROS; D ES H, HALOGENO, HIDROXILO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ETIL-ESTER DEL ACIDO [2-(2-CLORO-FENIL)-3H-BENZOIMIDAZOL-5-IL]-CARBAMICO, ETIL-ESTER DEL ACIDO [2-(4-METOXI-2-METIL-FENIL)-3H-BENZOIMIDAZOL-5-IL]-CARBAMICO, ETIL-ESTER DEL ACIDO [2-(2,6-DIMETIL-FENIL)-3H-BENZOIMIDAZOL-5-IL]-CARBAMICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) SIENDO UTILES EN EL TRATAMIENTO DE TOLERANCIA DETERIORADA A LA GLUCOSA, DIABETES TIPO 2, OBESIDAD, ANOREXIA NERVIOSAREFERS TO COMPOUNDS OF FORMULA A-L1-B-C-D, WHERE A IS AN ALKYL (C1-C20), ALCOXYL (C1-C20), CYCLOALKYL (C3-C12), AMONG OTHERS; L1 ES - (CH2) n- (CR4R4 ') p- (CH2) mN (R3) -, - (CH2) n- (CR4R4') p- (CH2) mN (R3) -C (S) -, - C (NH) -N (R3) - (CH2) n- (CR4R4 ') p- (CH2) m-, AMONG OTHERS, WHERE R3 IS HO LOWER ALKYL (C1-C7); m, n AND p ARE EACH FROM 0 TO 2; R4 AND R4 'ARE EACH H, HALOGEN, HYDROXYL, LOWER ALCOXYL (C1-C7), AMONG OTHERS; B IS A COMPOUND OF FORMULA (i), (ii), AMONG OTHERS, WHERE X1 AND X2 'ARE EACH O, NH, S, AMONG OTHERS; X1 ', X2, X3 AND X4 ARE EACH NO CH; C IS A COMPOUND OF FORMULA (iii), ARYL (C6-C14), AMONG OTHERS, WHERE R1 IS H, CN, HALOGEN, CF3, AMONG OTHERS; R'1, R2 AND R'2 ARE EACH H, HALOGEN, CF3, LOWER ALKYL (C1-C7), AMONG OTHERS; D IS H, HALOGEN, HYDROXYL, CN, AMONG OTHERS. PREFERRED COMPOUNDS ARE: [2- (2-CHLORO-PHENYL) -3H-BENZOIMIDAZOL-5-IL] -CARBAMIC ACID ETHYL-ESTER [2- (4-METHOXY-2-METHYL-PHENYL) ACID ETHYL-ESTER -3H-BENZOIMIDAZOLE-5-IL] -CARBAMIC, ETHYL-ESTER OF ACID [2- (2,6-DIMETHYL-PHENYL) -3H-BENZOIMIDAZOL-5-IL] -CARBAMIC, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF ACIL-COA-DIACIL-GLICEROL 1 (DGAT1) ACIL-TRANSFERASE, BEING USEFUL IN THE TREATMENT OF DETERIORATED GLUCOSE TOLERANCE, TYPE 2 DIABETES, OBESITY, ANOREXIA NERVOSA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82998006P | 2006-10-18 | 2006-10-18 | |
US95234107P | 2007-07-27 | 2007-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080888A1 true PE20080888A1 (en) | 2008-08-26 |
Family
ID=39276877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001396A PE20080888A1 (en) | 2006-10-18 | 2007-10-16 | HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1) |
Country Status (15)
Country | Link |
---|---|
US (1) | US8222248B2 (en) |
EP (1) | EP2074089B1 (en) |
JP (1) | JP5298022B2 (en) |
KR (1) | KR20090071642A (en) |
AR (1) | AR063311A1 (en) |
AU (1) | AU2007311087B2 (en) |
BR (1) | BRPI0718478A2 (en) |
CA (1) | CA2666880A1 (en) |
CL (1) | CL2007002974A1 (en) |
ES (1) | ES2440253T3 (en) |
MX (1) | MX2009004047A (en) |
PE (1) | PE20080888A1 (en) |
RU (1) | RU2009118489A (en) |
TW (1) | TW200829563A (en) |
WO (1) | WO2008048991A2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ587106A (en) | 2004-12-14 | 2012-03-30 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
EP1966221A1 (en) | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
ES2356097T3 (en) | 2006-05-30 | 2011-04-04 | Astrazeneca Ab | 5-PHENYLAMINE-1,3,4-OXADIAZOL-2-ILCARBONYLAMINO-4-FENOXI-CYCLHEXANCARBOXYL ACIDS SUBSTITUTED AS INHIBITORS OF THE COENZYME ACILTRANSPHERASE DIACILGLYCEROLA. |
NZ572585A (en) | 2006-05-30 | 2011-02-25 | Astrazeneca Ab | 1,3,4-Oxadiazole derivatives as DGAT1 inhibitors |
KR20100099738A (en) | 2007-12-20 | 2010-09-13 | 아스트라제네카 아베 | Carbamoyl compounds as dgat1 inhibitors 190 |
WO2009112445A1 (en) * | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
US20110301192A1 (en) * | 2008-10-01 | 2011-12-08 | The Regents Of The University Of California | Inhibitors of Cyclin Kinase Inhibitor p21 |
GB0821913D0 (en) | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
US20120022057A1 (en) * | 2009-03-18 | 2012-01-26 | Schering Corporation | Bicyclic compounds as inhibitors of diacyglycerol acyltransferase |
TW201103895A (en) | 2009-06-19 | 2011-02-01 | Astrazeneca Ab | Chemical compounds |
JP2013500267A (en) * | 2009-07-23 | 2013-01-07 | ヴァンダービルト ユニバーシティー | Substituted benzimidazole sulfonamides and substituted indole sulfonamides as mGLuR4 enhancers |
KR101194995B1 (en) * | 2009-10-14 | 2012-10-29 | 주식회사 이큐스앤자루 | Novel 4-phenyl-benzimidazole or 4-phenyl-benzoxazole derivates or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical compositions for antivirus containing the same as an active gredient |
WO2011099832A2 (en) * | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
AU2011260097B2 (en) | 2010-06-01 | 2015-01-22 | Summit (Oxford) Limited | Compounds for the treatment of clostridium difficile associated disease |
CN104159587A (en) * | 2012-01-06 | 2014-11-19 | 南佛罗里达大学 | Compositions, methods of use, and methods of treatment |
KR102212923B1 (en) | 2012-12-21 | 2021-02-04 | 플렉시콘 인코퍼레이티드 | Compounds and methods for kinase modulation, and indications therefor |
WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
WO2015095477A1 (en) | 2013-12-19 | 2015-06-25 | Irm Llc | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis |
RS59007B1 (en) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridine inhibitors of ror-gamma |
WO2015166398A1 (en) * | 2014-04-30 | 2015-11-05 | Aurigene Discovery Technologies Limited | 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors |
WO2016061160A1 (en) | 2014-10-14 | 2016-04-21 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
CA2986930C (en) | 2015-06-24 | 2023-09-26 | Duke University | Chemical modulators of signaling pathways and therapeutic use |
ES2856931T3 (en) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | ROR-gamma modulators |
MX2018006223A (en) | 2015-11-20 | 2018-12-19 | Vitae Pharmaceuticals Inc | Modulators of ror-gamma. |
TWI757266B (en) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | Modulators of ror-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
CN110234640B (en) * | 2016-09-20 | 2023-04-07 | 利昂贝拉尔中心 | Benzimidazole derivatives as anticancer agents |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of ror gamma |
KR20200053481A (en) | 2017-07-24 | 2020-05-18 | 비타이 파마슈티컬즈, 엘엘씨 | Inhibitors of RORγ |
US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
WO2020023782A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
US10889571B2 (en) * | 2018-09-18 | 2021-01-12 | Terns, Inc. | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias |
WO2020120576A1 (en) * | 2018-12-11 | 2020-06-18 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | p38α AUTOPHOSPHORYLATION INHIBITORS |
WO2021007477A1 (en) | 2019-07-11 | 2021-01-14 | E-Scape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
MX2022009025A (en) * | 2020-01-28 | 2022-10-07 | Protego Biopharma Inc | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding. |
EP4143329A2 (en) | 2020-04-28 | 2023-03-08 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
CN116745267A (en) * | 2020-12-11 | 2023-09-12 | 跨膜蛋白16A有限公司 | Benzimidazole derivatives for the treatment of respiratory diseases |
WO2022265993A1 (en) | 2021-06-14 | 2022-12-22 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
TW202317546A (en) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
WO2023134708A1 (en) * | 2022-01-12 | 2023-07-20 | Beigene , Ltd. | Thiazolopyridyl amide derivatives as dna polymerase theta inhibitors |
EP4265247A1 (en) * | 2022-04-22 | 2023-10-25 | Université Paris Cité | Compounds inducing production of proteins by immune cells |
US11970468B1 (en) | 2023-10-23 | 2024-04-30 | King Faisal University | 2-(benzo[d]oxazol-2-yl)-N′-(3,5-dichlorobenzoyloxy)acetimidamide as an antimicrobial compound |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3551443A (en) * | 1968-10-30 | 1970-12-29 | Ciba Ltd | 2-phenylbenzoxazole derivatives |
JPH0678308B2 (en) * | 1985-04-24 | 1994-10-05 | 三共株式会社 | Phthalimide derivative and agricultural / horticultural germicide containing the same |
EA002357B1 (en) * | 1995-12-28 | 2002-04-25 | Фудзисава Фармасьютикал Ко., Лтд. | Benzimidazole derivatives |
US6369235B1 (en) | 1997-02-25 | 2002-04-09 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted benzimidazoles, and methods of use thereof, for the inhibition of HIV reverse transcription and for the treatment of HIV infection |
US6251689B1 (en) | 1998-05-14 | 2001-06-26 | Telik, Inc. | Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof |
JP2000095767A (en) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | Antagonist for gonadotrophic hormone-releasing hormone |
MXPA01012283A (en) * | 1999-06-23 | 2002-07-30 | Aventis Pharma Gmbh | Substituted benzimidazole. |
DE60034578D1 (en) | 1999-08-26 | 2007-06-06 | Us Health | SUBSTITUTED BENZIMIDAZOLE AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE |
DK1320522T3 (en) * | 2000-09-19 | 2006-04-03 | Moses Lee | Achiral analogs of CC-1065 and of duocarmycins as well as preparations and methods for their use |
WO2002046168A1 (en) | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
FR2821721B1 (en) * | 2001-03-08 | 2004-07-09 | Laurent Locatelli | COMPOSITION FOR ANIMAL FEED, USE OF THIS COMPOSITION, AND PRODUCT FOR ANIMAL FEED COMPRISING THIS COMPOSITION |
CA2441177A1 (en) | 2001-03-12 | 2002-09-19 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
DE60221866T2 (en) * | 2001-10-19 | 2008-05-29 | Ortho-Mcneil Pharmaceutical, Inc. | 2-PHENYL BENZIMIDAZOLE AND IMIDAZO-i4,5ö-PYRIDINE AS CDS1 / CHK2 INHIBITORS AND ADJUVANTIES IN CHEMOTHERAPY OR RADIATION THERAPY FOR THE TREATMENT OF CANCER |
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
AU2002366803A1 (en) | 2001-12-19 | 2003-07-09 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
WO2003106439A1 (en) | 2002-06-12 | 2003-12-24 | 株式会社ビーエフ研究所 | Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation |
AU2003252395A1 (en) * | 2002-08-06 | 2004-03-11 | Toray Industries, Inc. | Remedy or preventive for kidney disease and method of diagnosing kidney disease |
CA2509202A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
DE10306250A1 (en) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals |
WO2004098494A2 (en) | 2003-04-30 | 2004-11-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
PE20050157A1 (en) | 2003-05-20 | 2005-05-17 | Novartis Ag | DERIVATIVES OF N-ACIL NITROGEN HETEROCICLICOS AS LIGANDS OF THE PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) |
WO2005108370A1 (en) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | Benzene compounds |
DE602005025517D1 (en) | 2004-10-15 | 2011-02-03 | Bayer Healthcare Llc | PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO-ACID DERIVATIVES FOR THE TREATMENT OF OBESITAS |
CA2600570C (en) * | 2005-03-14 | 2011-12-06 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as .beta.-secretase inhibitors |
GT200600429A (en) | 2005-09-30 | 2007-04-30 | ORGANIC COMPOUNDS | |
JP2009001495A (en) * | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | 2-aryl-benzimidazole-5-carboxamide derivative |
WO2007056155A1 (en) * | 2005-11-03 | 2007-05-18 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
BRPI0707719A2 (en) * | 2006-02-10 | 2011-05-10 | Summit Corp Plc | use of a compound or a pharmaceutically acceptable salt thereof |
-
2007
- 2007-10-16 AR ARP070104573A patent/AR063311A1/en not_active Application Discontinuation
- 2007-10-16 PE PE2007001396A patent/PE20080888A1/en not_active Application Discontinuation
- 2007-10-17 AU AU2007311087A patent/AU2007311087B2/en not_active Ceased
- 2007-10-17 KR KR1020097010003A patent/KR20090071642A/en not_active Application Discontinuation
- 2007-10-17 TW TW096138922A patent/TW200829563A/en unknown
- 2007-10-17 JP JP2009533499A patent/JP5298022B2/en not_active Expired - Fee Related
- 2007-10-17 CA CA002666880A patent/CA2666880A1/en not_active Abandoned
- 2007-10-17 CL CL200702974A patent/CL2007002974A1/en unknown
- 2007-10-17 RU RU2009118489/04A patent/RU2009118489A/en not_active Application Discontinuation
- 2007-10-17 US US12/446,088 patent/US8222248B2/en not_active Expired - Fee Related
- 2007-10-17 ES ES07854118.2T patent/ES2440253T3/en active Active
- 2007-10-17 EP EP07854118.2A patent/EP2074089B1/en not_active Not-in-force
- 2007-10-17 BR BRPI0718478-6A2A patent/BRPI0718478A2/en not_active IP Right Cessation
- 2007-10-17 MX MX2009004047A patent/MX2009004047A/en not_active Application Discontinuation
- 2007-10-17 WO PCT/US2007/081607 patent/WO2008048991A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP5298022B2 (en) | 2013-09-25 |
MX2009004047A (en) | 2009-07-21 |
JP2010506950A (en) | 2010-03-04 |
US20110046133A1 (en) | 2011-02-24 |
AU2007311087B2 (en) | 2012-03-01 |
CL2007002974A1 (en) | 2008-05-23 |
BRPI0718478A2 (en) | 2013-11-26 |
TW200829563A (en) | 2008-07-16 |
KR20090071642A (en) | 2009-07-01 |
RU2009118489A (en) | 2010-11-27 |
AR063311A1 (en) | 2009-01-21 |
EP2074089A2 (en) | 2009-07-01 |
WO2008048991A3 (en) | 2008-07-10 |
ES2440253T3 (en) | 2014-01-28 |
WO2008048991A2 (en) | 2008-04-24 |
EP2074089B1 (en) | 2013-09-18 |
US8222248B2 (en) | 2012-07-17 |
AU2007311087A1 (en) | 2008-04-24 |
CA2666880A1 (en) | 2008-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080888A1 (en) | HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1) | |
PE20061353A1 (en) | SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS | |
PE20110303A1 (en) | DERIVATIVES OF HETEROARYL ACETAMIDES AS GLUCOKINASE ACTIVATORS | |
PE20080906A1 (en) | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS | |
CO5700757A2 (en) | DERIVATIVES OF (3-OXO-3,4-DIHIDRO-QUINOXALIN-2-IL-AMINO) -BENZAMIDE AND RELATED COMPOUND, AS INHIBITORS OF GLUCOGEN PHOSPHORILASE FOR THE TREATMENT OF DIABETES AND OBESITY | |
PE20070135A1 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ASPARTILE PROTEASES | |
PE20091901A1 (en) | GLUCOKINASE ACTIVATORS | |
MX2011011485A (en) | Nematocidal sulfonamides. | |
ES2570756T3 (en) | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and use as kinase inhibitors | |
PE20070136A1 (en) | COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1 | |
PE20080538A1 (en) | FUSED HETEROCYCLIC DERIVATIVE AND ITS USE | |
ECSP055987A (en) | HETEROARILCARBAMOILBENCENO DERIVATIVES | |
PE20080418A1 (en) | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF THE HEDGEHOG PATH | |
PE20141005A1 (en) | 1,3-OXAZINES AS INHIBITORS OF BACE1 AND / OR BACE2 | |
MX2013006101A (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof. | |
PE20070189A1 (en) | AMINO-5-HETEROARYL COMPOUND (5 MEMBERS) IMIDAZOLONE AND ITS USE FOR ß-SECRETASE MODULATION | |
PE20091842A1 (en) | PYRROLIDINONES AS GLUCOKINASE ACTIVATORS | |
PE20120229A1 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEASE ASPARTIC | |
PE20120635A1 (en) | DIHYDROPIRAZOLONES SUBSTITUTED AS INHIBITORS OF HIF-PROPIL-4-HYDROXYLASES | |
PE20121500A1 (en) | 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS INHIBITORS OF BACE 1 AND / OR BACE 2 | |
PE20121157A1 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | |
AR075022A1 (en) | OXADIAZOLE DERIVATIVES AS AGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS (S1P1) | |
ECSP088129A (en) | NOVEDOUS DERIVATIVE OF HETEROCICLIDEN ACETAMIDA | |
PE20140703A1 (en) | HETEROARYL DERIVATIVES AS MODULATORS OF NACHR ALPHA 7 | |
PE20090601A1 (en) | PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |